An Optimizing Pain Management in Knee Osteoarthritis Through Opioid-Sparing Therapeutic Approaches – A Review

Knee osteoarthritis is a chronic progressive musculoskeletal disorder that primarily affect the knee joint which is characterized by gradual destruction of articular cartilage, results in narrowing of joint space, osteophyte formation and structural alterations in the subchondrial bone. Based on its etiology knee osteoarthritis is classified into primary osteoarthritis and secondary osteoarthritis. Primary osteoarthritis, also referred to as idiopathic osteoarthritis, develops without an identifiable underlying cause and is mainly associated with age-related degeneration of the articular cartilage. Secondary osteoarthritis caused by a certain event or an underlying condition which damages the cartilage [1,2]. With disease progression, individuals commonly experience persistent knee pain, joint stiffness, swelling, reduced flexibility, and difficulty performing everyday activities. These symptoms gradually impair mobility, limit functional independence, and negatively influence overall quality of life [3,4]. The global burden of knee osteoarthritis is increasing steadily owing to population ageing, increasing obesity, sedentary behavior, and longer life expectancy. The condition is reported more frequently in elderly population, female patients, individuals struggling with obesity and peope who have previously suffered trauma to the knee. Chronic knee pain also restricts activities such as walking, sitting, climbing stairs, sleeping, standing and performing occupational works [5,6]. Pain is the predominant symptom of knee osteoarthritis and is the principal reason patients seek medical attention. Chronic pain may lead to reduced physical activity, muscle weakness, sleep disturbance, anxiety, depression, and social isolation. Effective pain management is therefore essential to maintain functional ability and improve patient well-being [7,8]. Opioid-sparing therapeutic approaches aim to reduce opioid exposure while achieving adequate pain through multimodal treatment strategies. Current management guidelines recommend combining non-pharmacological interventions with non-opioid medications to improve pain and quality of life. Opioid-sparing management includes both drug-based and non-drug-based treatment such as lifestyle modification, exercise therapy, weight reduction, physiotherapy, NSAID, Anti-inflammatory drugs, intra-articular injection etc [9,10].

1.1 CLINICAL MANIFESTATIONS

Figure 1: Clinical Manifestations of KOA

Figure 2: Pathophysiology of Knee Osteoarthritis

Figure 3: Stages of Osteoarthritis

Understanding the stages of the disease helps in selecting appropriate treatment strategies and preventing further progression.

1. Stage I – Early or Minor Osteoarthritis

In the early stage, there is minimal damage to the knee joint. Small osteophytes or bony growths may begin to develop, but the cartilage surface is usually preserved. Early lifestyle modification and exercise therapy may retard advancement of structural joint pathology [23,24].

Features:

• Mild or occasional knee discomfort
• Minimal joint stiffness
• No significant limitation of movement
• Early cartilage wear may be present
• Symptoms usually occur after heavy activity

2. Stage II – Mild Osteoarthritis

During this stage, cartilage degeneration becomes more noticeable and osteophyte formation increases. At this stage, non-pharmacological management and non-opioid analgesics are commonly recommended [25].

Features:

• Mild to moderate knee pain
• Morning stiffness
• Discomfort while walking or climbing stairs
• Mild swelling may occur
• Crepitus during joint movement
• Early narrowing of joint space on imaging

3. Stage III – Moderate Osteoarthritis

Moderate osteoarthritis is characterized by significant cartilage loss and increased joint inflammation. Pain becomes more frequent and daily activities may become difficult. Management usually requires a combination of pharmacological therapy, physiotherapy, rehabilitation, topical agents, NSAIDs, and intra-articular therapies [23,26].

Features:

• Persistent knee pain
• Reduced range of motion
• Joint stiffness and swelling
• Difficulty in walking and standing
• Muscle weakness around the knee
• Noticeable joint space narrowing
• Increased osteophyte formation

4. Stage IV – Severe Osteoarthritis

This is the advanced stage of knee osteoarthritis in which extensive cartilage destruction occurs. Patients often experience considerable disability, and surgical procedures may be required when conservative treatment is no longer effective [13,27].

Features:

• Severe continuous pain
• Marked joint stiffness
• Significant reduction in mobility
• Joint deformity
• Chronic inflammation
• Difficulty performing daily activities

LIMITATIONS OF OPIOID THERAPY IN KNEE OSTEOARTHRITIS

Opioid analgesics for knee osteoarthritis may provide temporary relief in moderate to severe pain. Their long-term use is associated with several risks and limitation. These medications do not prevent disease progression and their effectiveness often decreases with prolonged use. Recent research suggests chronic opioid use may be linked to faster cartilage and meniscus loss over time. These medications do not modify disease progression, and their analgesic effectiveness often declines with prolonged treatment because of diminishing physiological responsiveness [28,29]. Extended opioid use features a propensity to induce physical reliance and, in some individuals, opioid use disorder, thereby increasing the risk of misuse and addiction. Recurrently documented secondary complications encompass nausea, vomiting, constipation, dizziness, drowsiness, cognitive impairment, respiratory depression, and sleep disturbances. Older adults are especially susceptible to these effects, that may contribute to confusion, falls, fractures, and reduced functional independence [30,51]. Opioid induced hyperalgesia is a condition that occurs due to prolonged opioid use which makes a person more sensitive to pain. This condition increases sensitivity to pain instead of reducing it, another limitation of opioid therapy [31]. KOA is a chronic condition which requires long-term treatment, so current clinical guidelines recommend minimizing opioid use and administering safer opioid-sparing therapeutic approaches that incorporates pharmacological as well as non-pharmacological interventions such as exercise therapy, physiotherapy, multimodal pain management strategies etc [8,32].

Opioid-Sparing Therapeutic Approaches

Opioid-sparing therapy involves the use of non-opioid medications that reduce reliance on opioid medications while effectively controlling pain. Use of alternative treatment modalities minimizes adverse effects and often progress recovery time. Opioid-sparing management involves a multidimensional therapeutic strategy that combines both pharmacological and non-pharmacological treatment [23,26].

Conceptual distribution of opioid-sparing strategies in knee osteoarthritis

This pie chart provides a visual summary of the major components involved in opioid-sparing management of knee osteoarthritis.

Exercise Therapy (25%) represents the largest component, highlighting its central role in improving joint flexibility, muscle strength, balance, and functional ability. Exercise is widely recognized as a cornerstone of knee osteoarthritis management [33].

Physiotherapy (20%) emphasizes the purpose of structured rehabilitation techniques, including range-of-motion exercises, strengthening programs, gait training, and balance exercises, which help improve mobility and reduce disability [34].

Pharmacological Therapy (20%) includes non-opioid medications such as NSAIDs, acetaminophen, topical analgesics, duloxetine, and intra-articular therapies. These treatments help control pain while reducing dependence on opioid medications [35].

Weight Reduction (15%) highlights the benefits of maintaining a healthy body weight. Reducing excess weight decreases mechanical stress on the knee joint, thereby improving symptoms and slowing disease progression [19].

Rehabilitation Programs (10%) represent comprehensive interventions that combine exercise, education, and functional training to enhance independence and long-term treatment outcomes [36].

Assistive Devices and Other Measures (10%) include walking aids, knee braces, orthotic supports, lifestyle modifications, and supportive therapies that improve joint stability and reduce pain during daily activities [37,38].

3.1 Non-Pharmacological Treatment

Non-pharmacological treatment is considered a fundamental component in knee osteoarthritis management and is often recommended as the first-line approach for symptom control. These interventions focus on reducing pain, joint mobility improvement, strengthen muscles, enhance physical function, and slow disease progression without depending entirely on medications. Non-pharmacological strategies are especially important in opioid-sparing management because they help minimize long-term analgesic use and related adverse effects. Non-pharmacological treatment forms the foundation of comprehensive knee osteoarthritis management and works effectively alongside pharmacological therapy to improve pain relief, mobility, and overall patient outcomes [21,34].

1. Weight Reduction

Excess bodyweight may increase pressure on the knee joint during walking and daily activities. By reducing body weight, we can reduce mechanical strength on the joint, improves joint mobility and reduces pain [18].

2. Exercise Therapy

Regular exercises helps maintain joint flexibility, strengthen the muscle surrounding the knee, enhance balance, reduce stiffness and improves overall physical function. Commonly recommended exercises include aerobic exercises, stretching exercises, quadriceps strengthening exercises, resistance training, water-based training [16,33].

3. Assistive Devices

Supportive devices like walking sticks, knee braces, supportive footwear, orthotic shoe inserts, walkers etc, help reduce stress on the knee joint and improve stability during movement. All these devices may improve balance and decrease pain during walking [34].

4. Physiotherapy

Physiotherapy plays a major role in improving joint function and reducing disability. Techniques used in physiotherapy include muscle strengthening, range-of-motion exercise, balance exercises, manual therapy [34]. Physiotherapists design rehabilitation programs focus on strengthening muscles, correcting posture, improving gait and increasing joint mobility.

5. Yoga and Tai Chi

Mind body therapies may improve flexibility, muscle strength, posture and mental well-being. Regular participation may also reduce pain perception, improve physical function, and enhance overall quality of life [39,40].

6. Hot and Cold Therapy

Heat therapy may reduce joint stiffness and muscle pain while cold therapy helps decrease inflammation and swelling. Both methods provide temporary symptomatic relief and may be used as supportive treatments alongside other therapeutic interventions [15].

7. Occupational Modification

Patients who involved in activities requiring prolonged standing, squatting, kneeling or heavy lifting may need modifications in daily activities or working place to reduce joint strain. Regular rest periods and modification of physically demanding tasks help prevent joint overuse, reduce inflammation, and improve the ability of patients to perform daily occupational activities comfortably [44].

8. Rehabilitation Programs

Early rehabilitation may delay disease progression and reduce functional disability. Rehabilitation programs combine exercise, physiotherapy, education and functional training to improve independence and physical performance. Regular rehabilitation supports opioid-sparing pain management by improving functional recovery and decreasing dependence on long -term analgesic therapy [41,42].

3.2 Pharmacological Treatment

Pharmacological therapy is an integral therapeutic component of KOA and is principally directed toward attenuating pain, restoring articular function, controlling pain, and improving the patients’ health-related functional status. The main objective of pharmacological management is to minimize adverse effects and improving patient comfort.  Based on age, severity of pain, comorbidities, degree of inflammation and response to previous treatment, medications to be used are selected. Commonly prescribed drugs include acetaminophen, nonsteroidal anti-inflammatory drugs, topical analgesics, duloxetine, intra-articular corticosteroids, hyaluronic acid injections, and supportive enzyme preparations such as trypsin-chymotrypsin. Weak opioid combinations such as tramadol-acetaminophen preparations may be used in selected patients for short-term management of moderate pain when other therapies are insufficient [22,35].

1. Nonsteroidal anti-inflammatory drugs (NSAIDs)

Most widely utilized pharmacological option for knee osteoarthritis. They help to reduce pain and inflammation within the joint by inhibiting cyclooxygenase enzyme and decreasing prostaglandin synthesis, that drive the pain and inflammation. Commonly used NSAIDs for knee osteoarthritis are etoricoxib, diclofenac, ibuprofen, naproxen. Prolonged use of NSAIDs may cause gastrointestinal irritation, renal impairment, bleeding disorders, and cardiovascular complications in elderly patient [23].

2. Topical Analgesics

Topical medications like diclofenac gel, capsaicin cream, topical ketoprofen are particularly beneficial for patients who have poor tolerance to systemic NSAIDs. They provide localized pain relief by acting directly at the affected site with fewer systemic side effects. Topical agents reduce pain with minimal systemic absorption and fewer adverse effects compared to oral medications [43,44].

3. Acetaminophen

Central analgesic, commonly used for mild to moderate osteoarthritis pain. Acetaminophen acts mainly through central inhibition of pain pathways and produces analgesic and antipyretic effect. When drugs like NSAIDs are contraindicated, acetaminophen is used because it produces fewer gastrointestinal effects. However, excessive or prolonged use may result in liver toxicity, especially in individuals with pre-existing liver disease or chronic alcohol consumption [28,32].

4. Duloxetine

Duloxetine is a serotonin–norepinephrine reuptake inhibitor (SNRI) that provides analgesic effects by modulating central pain pathways. It is particularly advantageous for patients with persistent musculoskeletal pain, central sensitization, or coexisting depression, especially when NSAIDs are ineffective or not well tolerated [45,46].                                         

5. Intra-articular corticosteroid injection

Corticosteroid injections used for short-term relief of severe pain and inflammation. Intra-articular corticosteroid injection is directly injected to the joint to reduce synovial inflammation and improve mobility temporarily. Corticosteroid injections may provide rapid but temporary symptom relief and improve joint movement This injection should be used cautiously because excessive use may contribute to cartilage damage [47].

6. Hyaluronic acid injection

Also known as Viscosupplementation that improves joint lubrication and shock absorption. Hyaluronic injection may relieve pain and improve joint mobility in selected patients with slight to moderate knee pain. Although these injections can temporarily improve joint function and mobility, repetitive usage should be strictly restricted because routine use can accelerate cartilage breakdown and joint trauma [26,47].

7. Trypsin-chymotrypsin

A proteolytic enzyme combination with anti-inflammatory and anti-edematous properties. Trypsin-chymotrypsin helps reduce pain, tissue swelling and inflammation by breaking down inflammatory proteins and promotes healing. Commonly used as supportive therapy along with analgesics and NSAIDs [48].

8. Platelet -rich plasma therapy

Platelet-rich plasma therapy involves the injection of concentrated platelets obtained from the patient’s own blood into the affected knee joint therapy is an autologous biologic treatment contains growth factors and bioactive proteins that may reduce inflammation and support tissue repair. This injection is increasingly being explored as regenerative treatment option in knee osteoarthritis management [49,50].

9. Opioid and weak opioid combination therapy

Weak opioid combinations, such as tramadol–acetaminophen formulations (e.g., Ultracet Semi), may be considered for short-term treatment of moderate-to-severe pain when satisfactory symptom control remains unattainable with non-opioid therapies. These agents act on central opioid receptors to modify pain perception. However, prolonged therapy is connected with addiction, tolerance, constipation, dizziness, sedation, respiratory depression, and a higher risk of misuse. Therefore, contemporary evidence-based recommendations advocate limiting their use to carefully selected patients and restricting the treatment whenever possible [31,51].

10. Multimodal Analgesic Therapy

Multimodal analgesic therapy combines medications with different mechanisms of action to optimize analgesic efficacy while minimizing medication-associated adverse events. Depending on the patient's clinical condition, treatment may include NSAIDs, acetaminophen, topical analgesics, duloxetine, proteolytic enzyme preparations, and intra-articular therapies alongside non-pharmacological interventions. This integrated approach enhances pain relief, improves functional recovery, and supports long-term opioid-sparing management [23,35].

3.3 Guideline Recommendations and Treatment Algorithm

Contemporary clinical guidelines recommend a comprehensive and multimodal approach for knee osteoarthritis management. The main objectives of treatment are to reduce pain, preserve joint function, maintain mobility, and enhance the patients’ health-related functional wee-being. Professional organizations, including the American College of Rheumatology (ACR), Osteoarthritis Research Society International (OARSI), European Alliance of Associations for Rheumatology (EULAR), and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO), recommend integrating pharmacological and non-pharmacological interventions according to disease severity, clinical presentation, and individual patient characteristics [3,4]. Current recommendations identify non-pharmacological interventions as the cornerstone of treatment and advise their implementation in all patients irrespective of disease stage. Patient education and self-management programs are encouraged because they improve disease awareness, treatment adherence, and participation in long-term care. Exercise therapy, including aerobic, strengthening, flexibility, and balance exercises, is strongly recommended because it reduces pain, improves joint function, and enhances physical performance. Physiotherapy, rehabilitation programs, and assistive devices may further improve mobility, stability, and independence in daily activities [36,38]. When symptoms remain inadequately controlled despite appropriate non-pharmacological management, pharmacological treatment may be introduced. Topical NSAIDs are commonly recommended as first-line pharmacological therapy because they provide effective analgesia with fewer systemic adverse effects. Acetaminophen may be considered for selected patients with mild pain, whereas duloxetine may be beneficial for individuals with persistent chronic pain or central pain sensitization. Intra-articular corticosteroid injections can provide temporary relief during acute exacerbations, while hyaluronic acid injections may be considered for carefully selected patients who continue to experience symptoms despite conservative treatment [9,46]. A key feature of contemporary guidelines is the emphasis on minimizing opioid exposure. Long term opioid therapy is generally discouraged because the potential risks including dependence, tolerance, cognitive impairment, falls, and other treatment-related complications. Consequently, opioids should be reserved for exceptional circumstances in carefully selected patients when alternative therapeutic options are ineffective, contraindicated, or unavailable [30,51]. Patients who continue to experience significant pain, progressive functional limitation, and impaired quality of life despite optimal conservative treatment may require surgical evaluation. Surgical procedures, including osteotomy, unicompartmental knee arthroplasty, and total knee arthroplasty, may be considered according to disease severity, structural joint damage, and patient-specific factors. The overall treatment pathway recommended by current guidelines promotes a stepwise progression from lifestyle modification and rehabilitation to pharmacological therapy and, when necessary, surgical intervention while maintaining an opioid-sparing treatment philosophy throughout the continuum of care [22,24].

Knee Osteoarthritis

↓

Clinical Assessment and Evaluation of Disease Severity

↓

Patient Education and Self-Management

↓

Exercise Therapy + Weight Reduction + Physiotherapy

↓

Persistent Symptoms

↓

Topical NSAIDs

↓

Oral NSAIDs / Acetaminophen / Duloxetine

↓

Inadequate Symptom Control

↓

Intra-Articular Corticosteroid or Hyaluronic Acid Injection

↓

Persistent Functional Limitation and Advanced Disease

↓

Surgical Evaluation and Management

↓

Opioid Therapy Only in Carefully Selected Patients and for Limited Duration Flow Chart 1: Guideline-Based Treatment Algorithm

 3.4 SURGICAL MANAGEMENT

When conservative treatments fail to provide adequate pain relief or functional improvement in knee osteoarthritis patients, surgical management is considered. Surgical intervention is considered for patients with knee osteoarthritis who continue to experience severe pain, progressive functional impairment, and poor quality of life despite receiving appropriate conservative treatment. The choice of procedure depends on several factors, including the patient's age, extent of joint damage, level of physical activity, and overall health status. Although surgical treatment can provide substantial improvement in pain and function, potential complications such as infection, prosthesis loosening, thromboembolic events, joint stiffness, and persistent pain should be considered. Careful patient selection, proper surgical technique, and regular follow-up are important for achieving successful long-term outcomes [7,13].

1. Arthroscopic surgery

Minimally invasive procedure used to diagnose and treat joint problems, a small camera and surgical instruments are inserted into the knee joint through small incisions. It may be used to remove loose cartilage fragments. Repair meniscal injuries or clean the joint surface. As it does not stop disease progression, arthroscopy is not recommended solely for degenerative joint disease [12,27].

2. Partial knee replacement

Also known as unicompartmental knee arthroplasty, is performed when osteoarthritis affects only one compartment of the knee. Only damaged portion of the joint is replaced with an artificial implant while preserving healthy bone and ligaments. Several advantages of this procedure include faster recovery, smaller surgical incision. Better joint mobility, reduced blood loss [13].

3. Osteotomy

Osteotomy is a joint-preserving surgical procedure in which the bone is cut and realigned to redistribute mechanical load away from the damaged compartment of the knee. This surgery can alleviate pain, enhance joint function, and postpone the requirement for knee arthroplasty, particularly in younger and more active patients [6,12].

4. Total knee replacement

Total knee arthroplasty is recognized as the standard definitive operative intervention for end stage knee osteoarthritis associated with severe pain, marked joint deformity, significant functional limitation, and failure of conservative therapy. In this procedure, damaged cartilage and bone surfaces are removed and replaced with artificial prosthetic components made of metal and polyethylene. Total knee replacement can significantly improve pain, mobility and quality of life [13,47].

DISCUSSION

Hunter and Bierma-Zeinstra described knee osteoarthritis as a progressive joint disorder characterized by structural degeneration, chronic pain, and functional impairment that substantially affect daily functioning. Their review emphasized that the increasing prevalence of osteoarthritis has created a growing demand for effective long-term management strategies [5]. Kolasinski et al. highlighted the importance of non-pharmacological interventions as the cornerstone of osteoarthritis management. The authors emphasized that exercise therapy, weight management, self-management programs, and patient education demonstrated beneficial effects on reducing symptoms and improving physical function. Their recommendations reflect a shift toward patient-centered care and support the use of opioid-sparing approaches as part of routine clinical practice [10].

Bannuru et al. reported that treatment should be individualized according to disease severity, patient characteristics, and associated comorbidities. Their recommendations supported the integration of multiple therapeutic modalities to achieve optimal pain relief and functional improvement. They suggested that combining pharmacological and non-pharmacological therapies provides more improvement than relying on a single treatment modality [23].

Arden et al. reviewed international clinical guidelines and found considerable agreement regarding the importance of exercise therapy, weight management, and appropriate pharmacological treatment. Their findings demonstrated that multimodal management strategies represent an effective approach for controlling symptoms while minimizing the risks associated with long-term opioid use [9].

Fernandes et al. emphasized that non-pharmacological interventions remain essential components of osteoarthritis care. The authors reported that structured exercise programs, rehabilitation strategies, and lifestyle modifications contribute significantly to improvements in pain, mobility, and physical function. These findings may also abate the need for prolonged analgesic therapy and support long-term disease management. Fransen et al. findings indicate that consistent participation in structured physical activity helps maintain functional independence, reduces disability, and supports better long-term clinical outcomes in individuals with knee osteoarthritis [16].

Collectively, the reviewed literature suggests that opioid-sparing therapeutic approaches provide an effective and sustainable strategy for managing knee osteoarthritis. The integration of evidence-based pharmacological therapies with exercise, rehabilitation, weight management, and patient education appears to improve pain control while reducing reliance on opioid medications. Future studies should focus on personalized treatment strategies and emerging therapies that may further enhance long-term patient outcomes [37,42].

CONCLUSION

Knee osteoarthritis significantly affects physical function, mobility and overall quality of life. Although opioids were previously used for pain management, their prolonged use is associated with important risks including tolerance, dependence and other serious adverse effects. Opioid -sparing therapeutic approaches provide safer and more effective alternatives for managing osteoarthritis pain. Multimodal pain management plays a vital role in optimizing treatment outcomes because it targets multiple pain pathways simultaneously while minimizing medication-related adverse effects. Multimodal approach can significantly improve pain relief and functional outcomes. Advances in regenerative medicine, rehabilitation technologies and personalized therapeutic approaches may further improve the future management of knee osteoarthritis.

REFERENCES

1. Allen KD, Ambrose KR, Booker SQ, Buck AN, Huffman KF. Non-pharmacological pain management for osteoarthritis: review update. Curr Rheumatol Rep. 2025;27(1):19.
2. Gibbs AJ, Gray B, Wallis JA, Taylor NF, Kemp JL, Hunter DJ, et al. Recommendations for the management of hip and knee osteoarthritis: a systematic review of clinical practice guidelines. Osteoarthritis Cartilage. 2023;31(10):1280-1292.
3. Ferreira RM, Martins PN, Gonçalves RS. Non-pharmacological and non-surgical interventions to manage patients with knee osteoarthritis: an umbrella review 5-year update. Osteoarthritis Cartilage Open. 2024;6(3):100497.
4. Gibbs AJ, Gray B, Wallis JA, Taylor NF, Kemp JL, Hunter DJ, et al. Recommendations for the management of hip and knee osteoarthritis: a systematic review of clinical practice guidelines. Osteoarthritis Cartilage. 2023;31(10):1280-1292.
5. Hunter DJ, Bierma-Zeinstra SMA. Osteoarthritis. Lancet. 2019;393(10182):1745-1759.
6. Loeser RF, Collins JA, Diekman BO. Ageing and the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016;12(7):412-420.
7. Katz JN, Arant KR, Loeser RF. Diagnosis and treatment of hip and knee osteoarthritis: a review. JAMA. 2021;325(6):568-578.
8. Da Costa BR, Pereira TV, Saadat P, Rudnicki M, Iskander SM, Bodmer NS, et al. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. BMJ. 2021;375: n2321.
9. Arden NK, Perry TA, Bannuru RR, Bruyère O, Cooper C, Haugen IK, et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI guidelines. Nat Rev Rheumatol. 2021;17(1):59-66.
10. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2020;72(2):149-162.
11. Martel-Pelletier J, Barr AJ, Cicuttini FM, Conaghan PG, Cooper C, Goldring MB, et al. O Fransen M, McConnell S, Harmer AR, Van der Esch M, Simic M, Bennell KL. Exercise for osteoarthritis of the knee. Cochrane Database Syst Rev. 2015;(1):CD004376.
12. Felson DT. Clinical practice: osteoarthritis of the knee. N Engl J Med. 2006;354(8):841-848.
13. Hannon CP, Goodman SM, Austin MS, Yates A Jr, Guyatt G, Aggarwal VK, et al. 2023 American College of Rheumatology and American Association of Hip and Knee Surgeons clinical practice guideline for the optimal timing of elective hip or knee arthroplasty. Arthritis Rheumatol. 2023;75(11):1877-1888.
14. Conaghan PG, Cook AD, Hamilton JA, Tak PP. Therapeutic options for targeting inflammatory osteoarthritis pain. Nat Rev Rheumatol. 2019;15(6):355-363.
15. Martel-Pelletier J, Pelletier JP. Is osteoarthritis a disease involving only cartilage or other articular tissues? Eklem Hastalik Cerrahisi. 2010;21(1):2-14.
16. Fransen M, McConnell S, Harmer AR, Van der Esch M, Simic M, Bennell KL. Exercise for osteoarthritis of the knee. Cochrane Database Syst Rev. 2015;(1):CD004376.
17. Mobasheri A, Batt M. An update on the pathophysiology of osteoarthritis. Ann Phys Rehabil Med. 2016;59(5-6):333-339.
18. Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, et al. Osteoarthritis: new insights. Part 1: the disease and its risk factors. Ann Intern Med. 2000;133(8):635-646.
19. Creamer P, Hochberg MC. Osteoarthritis. Lancet. 1997;350(9076):503-508.
20. Fransen M, Bridgett L, March L, Hoy D, Penserga E, Brooks P. The epidemiology of osteoarthritis in Asia. Int J Rheum Dis. 2011;14(2):113-121. steoarthritis. Nat Rev Dis Primers. 2016; 2:16072.
21. Hochberg MC. New directions in symptomatic therapy for patients with osteoarthritis. Curr Rheumatol Rep. 2002;4(6):451-457.
22. Bruyere O, Honvo G, Veronese N, Rizzoli R, Cooper C, Reginster JY. An updated algorithm recommendation for the management of knee osteoarthritis. Semin Arthritis Rheum. 2019;49(3):337-350.
23. Bannuru RR, Schmid CH, Kent DM, Vaysbrot EE, Wong JB, McAlindon TE. Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis. Ann Intern Med. 2015;162(1):46-54.
24. Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-1589.
25. Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JWJ, Dieppe P, et al. EULAR recommendations 2003: an evidence-based approach to the management of knee osteoarthritis. Ann Rheum Dis. 2003;62(12):1145-1155.
26. Jevsevar DS, Donnelly P, Brown GA, Cummins DS. Viscosupplementation for osteoarthritis of the knee: a systematic review of the evidence. J Bone Joint Surg Am. 2015;97(24):2047-2060.
27. Bijlsma JWJ, Berenbaum F, Lafeber FPJG. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377(9783):2115-2126.
28. Chou R, McDonagh MS, Nakamoto E, Griffin J. Analgesics for osteoarthritis: an update of the 2006 comparative effectiveness review. AHRQ Comparative Effectiveness Review. 2011;(38).
29. Hunter DJ. Pharmacologic therapy for osteoarthritis—the era of disease modification. Nat Rev Rheumatol. 2011;7(1):13-22.
30. Welsch P, Petzke F, Klose P, Häuser W. Opioids for chronic osteoarthritis pain: an updated systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks double-blind duration. Eur J Pain. 2020;24(4):685-703.
31. Abdel Shaheed C, Awal W, Zhang G, Gilbert SE, Gallacher D, McLachlan A, et al. Efficacy, safety, and dose-dependence of the analgesic effects of opioid therapy for people with osteoarthritis: systematic review and meta-analysis. Med J Aust. 2022;216(6):305-311.
32. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken). 2012;64(4):465-474.
33. Weng Q, Goh SL, Wu J, Persson MSM, Wei J, Sarmanova A, et al. Comparative efficacy of exercise therapy and oral non-steroidal anti-inflammatory drugs and paracetamol for knee or hip osteoarthritis: a network meta-analysis of randomised controlled trials. Br J Sports Med. 2023;57(15):990-996.
34. Bijlsma JWJ, Berenbaum F, Lafeber FPJG. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377(9783):2115-2126.
35. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum. 2001;44(6):1237-1247.
36. Pitsillides A, Stasinopoulos D, Giannakou K. The effects of cognitive behavioural therapy delivered by physical therapists in knee osteoarthritis pain: a systematic review and meta-analysis of randomized controlled trials. J Bodyw Mov Ther. 2021;25:157-164.
37. Safari R, Jackson J, Sheffield D. Digital self-management interventions for people with osteoarthritis: systematic review with meta-analysis. J Med Internet Res. 2020;22(7):e15365.
38. Uritani D, Koda H, Sugita S. Effects of self-management education programmes on self-efficacy for osteoarthritis of the knee: a systematic review of randomised controlled trials. BMC Musculoskelet Disorder. 2021;22(1):515.
39. Majeed MH, McMillan V, et al. Cognitive behavioural therapy and pain coping skills training for osteoarthritis knee pain management: a systematic review. J Health Psychol. 2018;23(5):691-700.
40. Chen J, Liu A, Zhou Q, Yu W, Guo T, Jia Y, et al. Acupuncture for the treatment of knee osteoarthritis: an overview of systematic reviews. Int J Gen Med. 2021; 14:8481-8494.
41. Ajrawat P, Radomski L, Bhatia A, Peng P, Nath N, Gandhi R. Radiofrequency procedures for the treatment of symptomatic knee osteoarthritis: a systematic review. Pain Med. 2020;21(2):333-348.
42. Zhang ZY, Tian L, He K, Xu L, Wang XQ, Huang L, et al. Digital rehabilitation programs improve therapeutic exercise adherence for patients with musculoskeletal conditions: a systematic review with meta-analysis. J Orthop Sports Phys Ther. 2022;52(11):726-739.
43. Wolff GD, Christophersen C, Brown SM, Mulcahey MK. Topical nonsteroidal anti-inflammatory drugs in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Phys Sportsmed. 2021;49(4):381-391.
44. Chen B, Duan J, Wen S, Pang J, Zhang M, Zhan H, et al. An updated systematic review and meta-analysis of duloxetine for knee osteoarthritis pain. Clin J Pain. 2021;37(11):852-862.
45. Chen L, Gong M, Liu G, Xing F, Liu J, Xiang Z. Efficacy and tolerability of duloxetine in patients with knee osteoarthritis: a meta-analysis of randomised controlled trials. Intern Med J. 2019;49(12):1514-1523.
46. Osani MC, Bannuru RR. Efficacy and safety of duloxetine in osteoarthritis: a systematic review and meta-analysis. Korean J Intern Med. 2019;34(5):966-973.
47. Anil U, Markus DH, Hurley ET, Manjunath AK, Alaia MJ, Campbell KA, et al. The efficacy of intra-articular injections in the treatment of knee osteoarthritis: a network meta-analysis of randomized controlled trials. Knee. 2021; 32:173-182.
48. Thorlund JB, Simic M, Pihl K, Berthelsen DB, Day R, Koes B, et al. Similar effects of exercise therapy, nonsteroidal anti-inflammatory drugs, and opioids for knee osteoarthritis pain: a systematic review with network meta-analysis. J Orthop Sports Phys Ther. 2022;52(4):207-216.
49. Hohmann E, Tetsworth K, Glatt V. Is platelet-rich plasma effective for the treatment of knee osteoarthritis? A systematic review and meta-analysis of level 1 and 2 randomized controlled trials. Eur J Orthop Surg Traumatol. 2020;30(6):955-967.
50. Tang JZ, Nie MJ, Zhao JZ, Zhang GC, Zhang Q, Wang B. Platelet-rich plasma versus hyaluronic acid in the treatment of knee osteoarthritis: a meta-analysis. J Orthop Surg Res. 2020;15(1):403.
51. Osani MC, Lohmander LS, Bannuru RR. Is there any role for opioids in the management of knee and hip osteoarthritis? A systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2021;73(10):1413-1424.